HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 3 (2006), Issue 8 (August)

1. Radical prostatectomy in patients infected with human immunodeficiency virus.
   BJU Int, 98(2): 303-7. [Abstract] [Full-text]
2. Branched DNA technology in molecular diagnostics.
   Am J Clin Pathol, 126(3): 448-53. [Abstract] [Full-text]
3. Identification of a D-amino acid decapeptide HIV-1 entry inhibitor.
   Biochem Biophys Res Commun, 347(4): 909-15. [Abstract] [Full-text]
4. HIV-AIDS in minorities.
   Clin Chest Med, 27(3): 511-9, viii. [Abstract] [Full-text]
5. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma.
   J Natl Cancer Inst, 98(15): 1088-91. [Abstract] [Full-text]
6. Assessing the completeness of reporting of human immunodeficiency virus diagnoses in 2002-2003: capture-recapture methods.
   Am J Epidemiol, 164(4): 391-7. [Abstract] [Full-text]
7. Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities.
   Lancet, 368(9534): 511-21. [Abstract] [Full-text]
8. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.
   Lancet, 368(9534): 505-10. [Abstract] [Full-text]
9. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.
   Lancet, 368(9534): 489-504. [Abstract] [Full-text]
10. Absorptive capacity and disbursements by the Global Fund to Fight AIDS, Tuberculosis and Malaria: analysis of grant implementation.
    Lancet, 368(9534): 483-8. [Abstract] [Full-text]
11. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
    Lancet, 368(9534): 476-82. [Abstract] [Full-text]
12. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Lancet, 368(9534): 466-75. [Abstract] [Full-text]
13. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.
    Lancet, 368(9534): 459-65. [Abstract] [Full-text]
14. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.
    Lancet, 368(9534): 451-8. [Abstract] [Full-text]
15. Absence of detectable viremia in a perinatally HIV-1-infected teenager after discontinuation of antiretroviral therapy.
    J Allergy Clin Immunol, 118(2): 324-30. [Abstract] [Full-text]
16. Inhibition of viral assembly in murine cells by HIV-1 matrix.
    Virology, 352(1): 27-38. [Abstract] [Full-text]
17. Gene expression profiling of the host response to HIV-1 B, C, or A/E infection in monocyte-derived dendritic cells.
    Virology, 352(1): 86-99. [Abstract] [Full-text]
18. Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques.
    Virology, 352(1): 169-77. [Abstract] [Full-text]
19. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
    Virology, 352(1): 216-25. [Abstract] [Full-text]
20. Reciprocal transactivation between HIV-1 and other human viruses.
    Virology, 352(1): 1-13. [Abstract] [Full-text]
21. The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.
    Blood, 108(4): 1145-50. [Abstract] [Full-text]
22. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Arch Pediatr Adolesc Med, 160(8): 778-87. [Abstract] [Full-text]
23. A randomized controlled trial testing an HIV prevention intervention for Latino youth.
    Arch Pediatr Adolesc Med, 160(8): 772-7. [Abstract] [Full-text]
24. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients.
    Neurology, 67(3): 383-8. [Abstract] [Full-text]
25. Gag-Pol bearing a reverse transcriptase drug-resistant mutation influences viral genomic RNA incorporation into human immunodeficiency virus type 1 particles.
    J Gen Virol, 87: 2669-77. [Abstract] [Full-text]
26. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques.
    Am J Respir Crit Care Med, 174(4): 437-45. [Abstract] [Full-text]
27. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.
    JAMA, 296(6): 679-90. [Abstract] [Full-text]
28. A polymorphism that reduces RANTES expression is associated with protection from death in HIV-seropositive Ugandans with advanced disease.
    J Infect Dis, 194(5): 666-9. [Abstract] [Full-text]
29. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    J Infect Dis, 194(5): 661-5. [Abstract] [Full-text]
30. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
    J Infect Dis, 194(5): 642-50. [Abstract] [Full-text]
31. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.
    J Infect Dis, 194(5): 633-41. [Abstract] [Full-text]
32. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
    J Infect Dis, 194(5): 623-32. [Abstract] [Full-text]
33. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.
    J Infect Dis, 194(5): 612-22. [Abstract] [Full-text]
34. Metabolic and skeletal complications of HIV infection: the price of success.
    JAMA, 296(7): 844-54. [Abstract] [Full-text]
35. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
    JAMA, 296(7): 827-43. [Abstract] [Full-text]
36. Biology of CCR5 and its role in HIV infection and treatment.
    JAMA, 296(7): 815-26. [Abstract] [Full-text]
37. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    JAMA, 296(7): 806-14. [Abstract] [Full-text]
38. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
    JAMA, 296(7): 794-805. [Abstract] [Full-text]
39. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.
    JAMA, 296(7): 782-93. [Abstract] [Full-text]
40. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    JAMA, 296(7): 769-81. [Abstract] [Full-text]
41. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
    Int J Radiat Oncol Biol Phys, 66(1): 206-11. [Abstract] [Full-text]
42. A serological screening assay of human immunodeficiency virus type 1 antibodies based on recombinant protein p24-gp41 as a fusion protein expressed in Escherichia coli.
    J Biotechnol, 125(2): 295-303. [Abstract] [Full-text]
43. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
    Arch Intern Med, 166(15): 1632-41. [Abstract] [Full-text]
44. Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older.
    Arch Intern Med, 166(15): 1626-31. [Abstract] [Full-text]
45. Intra- and intersubtype alternative Pak2-activating structural motifs of human immunodeficiency virus type 1 Nef.
    J Virol, 80(17): 8824-9. [Abstract] [Full-text]
46. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    J Virol, 80(17): 8807-19. [Abstract] [Full-text]
47. Mobility of human immunodeficiency virus type 1 Pr55Gag in living cells.
    J Virol, 80(17): 8796-806. [Abstract] [Full-text]
48. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    J Virol, 80(17): 8745-62. [Abstract] [Full-text]
49. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.
    J Virol, 80(17): 8729-38. [Abstract] [Full-text]
50. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    J Virol, 80(17): 8450-8. [Abstract] [Full-text]
51. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes.
    J Virol, 80(17): 8411-21. [Abstract] [Full-text]
52. The experience of fatigue for adults living with HIV.
    J Clin Nurs, 15(9): 1123-31. [Abstract] [Full-text]
53. Effect of antifungal treatment on the prevalence of yeasts in HIV-infected subjects.
    J Med Microbiol, 55: 1279-84. [Abstract] [Full-text]
54. Critical care of immunocompromised patients: human immunodeficiency virus.
    Crit Care Med, 34(9): S245-50. [Abstract] [Full-text]
55. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART).
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102(3): 318-24. [Abstract] [Full-text]
56. Vaccine approaches to prevent tuberculosis.
    Scand J Immunol, 64(3): 243-50. [Abstract] [Full-text]
57. Improving anti-hepatitis C virus therapy.
    Expert Opin Biol Ther, 6(9): 923-33. [Abstract] [Full-text]
58. Pulmonary surfactant in patients with Pneumocystis pneumonia and acquired immunodeficiency syndrome.
    Crit Care Med, 34(9): 2370-6. [Abstract] [Full-text]
59. Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation.
    Virology, 352(2): 408-17. [Abstract] [Full-text]
60. Interleukin-10 inhibits HIV-1 LTR-directed gene expression in human macrophages through the induction of cyclin T1 proteolysis.
    Virology, 352(2): 485-92. [Abstract] [Full-text]
61. The G490E mutation in reverse transcriptase does not impact tRNA primer selection by HIV-1 with altered PBS and A-loop.
    Virology, 352(2): 380-9. [Abstract] [Full-text]
62. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
    Virology, 352(2): 438-49. [Abstract] [Full-text]
63. H. saimiri tyrosine-kinase interacting protein inhibits Tat function: a prototypic strategy for restricting HIV-1-induced cytopathic effects in immune cells.
    Virology, 352(2): 253-67. [Abstract] [Full-text]
64. CXCR4 tropic human immunodeficiency virus type 1 induces an apoptotic cascade in immature infected thymocytes that resembles thymocyte negative selection.
    Virology, 352(2): 268-84. [Abstract] [Full-text]
65. A quasi-lentiviral green fluorescent protein reporter exhibits nuclear export features of late human immunodeficiency virus type 1 transcripts.
    Virology, 352(2): 295-305. [Abstract] [Full-text]
66. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry.
    Virology, 352(2): 477-84. [Abstract] [Full-text]
67. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    J Infect Dis, 194: S59-64. [Abstract] [Full-text]
68. Rationale and uses of a public HIV drug-resistance database.
    J Infect Dis, 194: S51-8. [Abstract] [Full-text]
69. Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa.
    J Infect Dis, 194: S45-50. [Abstract] [Full-text]
70. HIV-1 load quantitation: a 17-year perspective.
    J Infect Dis, 194: S38-44. [Abstract] [Full-text]
71. Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.
    Bioorg Med Chem, 14(19): 6695-712. [Abstract] [Full-text]
72. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.
    Biochem Biophys Res Commun, 348(3): 1107-15. [Abstract] [Full-text]
73. Cell-based chemical genetic screen identifies damnacanthal as an inhibitor of HIV-1 Vpr induced cell death.
    Biochem Biophys Res Commun, 348(3): 1101-6. [Abstract] [Full-text]
74. An abdominal mass owing to Penicillium marneffei in an HIV-infected 7-year-old boy: case report.
    Ann Trop Paediatr, 26(3): 259-62. [Abstract] [Full-text]
75. Within and between race differences in lymphocyte, CD4+, CD8+ and neutrophil levels in HIV-uninfected children with or without HIV exposure in Europe and Uganda.
    Ann Trop Paediatr, 26(3): 169-79. [Abstract] [Full-text]
76. Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer.
    Blood, 108(5): 1643-51. [Abstract] [Full-text]
77. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection.
    Blood, 108(5): 1580-7. [Abstract] [Full-text]
78. Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: Simulation results.
    Sex Transm Dis, 33(9): 536-44. [Abstract] [Full-text]
79. The effect of venue sampling on estimates of HIV prevalence and sexual risk behaviors in men who have sex with men.
    Sex Transm Dis, 33(9): 545-50. [Abstract] [Full-text]
80. Coital bleeding and HIV risks among men and women in Cape Town, South Africa.
    Sex Transm Dis, 33(9): 551-7. [Abstract] [Full-text]
81. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus.
    Int J Cancer, 119(7): 1623-9. [Abstract] [Full-text]
82. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems.
    Alcohol Clin Exp Res, 30(9): 1520-6. [Abstract] [Full-text]
83. Communities' views on prerequisites for collaboration between modern and traditional health sectors in relation to STI/HIV/AIDS care in Zambia.
    Health Policy, 78(2): 330-9. [Abstract] [Full-text]
84. Ocular tuberculosis in acquired immunodeficiency syndrome.
    Am J Ophthalmol, 142(3): 413-8. [Abstract] [Full-text]
85. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring.
    Plast Reconstr Surg, 118(3): 55S-63S. [Abstract] [Full-text]
86. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.
    Plast Reconstr Surg, 118(3): 34S-45S. [Abstract] [Full-text]
87. Hemorheologic abnormalities associated with HIV infection: in vivo assessment of retinal microvascular blood flow.
    Invest Ophthalmol Vis Sci, 47(9): 3933-8. [Abstract] [Full-text]
88. Hemorheologic abnormalities associated with HIV infection: altered erythrocyte aggregation and deformability.
    Invest Ophthalmol Vis Sci, 47(9): 3927-32. [Abstract] [Full-text]
89. Kinetic dependence to HIV-1 entry inhibition.
    J Biol Chem, 281(35): 25813-21. [Abstract] [Full-text]
90. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication.
    J Biol Chem, 281(35): 25712-22. [Abstract] [Full-text]
91. Decreased prevalence of mixed cryoglobulinemia in the HAART era among HIV-positive, HCV-negative patients.
    J Med Virol, 78(10): 1257-61. [Abstract] [Full-text]
92. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    J Med Virol, 78(10): 1312-7. [Abstract] [Full-text]
93. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype.
    J Med Virol, 78(10): 1262-8. [Abstract] [Full-text]
94. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression.
    Clin Infect Dis, 43(7): 939-41. [Abstract] [Full-text]
95. Etiology of chronic diarrhea in antiretroviral-naive patients with HIV infection admitted to Norodom Sihanouk Hospital, Phnom Penh, Cambodia.
    Clin Infect Dis, 43(7): 925-32. [Abstract] [Full-text]
96. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
    Clin Infect Dis, 43(7): 904-10. [Abstract] [Full-text]
97. Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS.
    Br J Cancer, 95(5): 642-8. [Abstract] [Full-text]
98. Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis.
    J Infect Dis, 194(6): 846-54. [Abstract] [Full-text]
99. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
    J Infect Dis, 194(6): 760-3. [Abstract] [Full-text]
100. Gonococcal lipooligosaccharide suppresses HIV infection in human primary macrophages through induction of innate immunity.
     J Infect Dis, 194(6): 751-9. [Abstract] [Full-text]
101. Inhibition of multidrug-resistant HIV-1 by interference with cellular S-adenosylmethionine decarboxylase activity.
     J Infect Dis, 194(6): 740-50. [Abstract] [Full-text]
102. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
     J Infect Dis, 194(6): 734-9. [Abstract] [Full-text]
103. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
     J Infect Dis, 194(6): 725-33. [Abstract] [Full-text]
104. American histoplasmosis in developing countries with a special focus on patients with HIV: diagnosis, treatment, and prognosis.
     Curr Opin Infect Dis, 19(5): 443-9. [Abstract] [Full-text]
105. Synthesis and antiviral evaluation of alkoxyalkyl esters of acyclic purine and pyrimidine nucleoside phosphonates against HIV-1 in vitro.
     Antiviral Res, 72(1): 10-9. [Abstract] [Full-text]
106. Preventing HIV, eliminating disparities among Hispanics in the United States.
     J Immigr Minor Health, 8(4): 313-8. [Abstract] [Full-text]
107. Prevalence of HIV and other sexually transmitted diseases among Colombian and Dominican female sex workers living in Catania, Eastern Sicily.
     J Immigr Minor Health, 8(4): 319-23. [Abstract] [Full-text]
108. Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya.
     Immunol Cell Biol, 84(5): 482-5. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.